Sotera Health (SHC) FY2025 results: revenue $1.2 billion, up 5.7% on the year
Sotera Health Co. (SHC) reported revenue of $1.2 billion for fiscal 2025, the year ended 31 December 2025, up 5.7% on the year before. Net income was $78 million, up 75.6%, and diluted earnings per share $0.27. The figures are the company's own, from the 10-K it filed with the SEC on 24 February 2026.
this yearthe year beforeHover a bar for its figure.
The year in brief
What management said about the year
Guidance figures: 7 new.
- Full-year revenue grew 5.7%: Constant currency growth was 5.2%, and management described the year as the 20th consecutive year of revenue growth.
- Adjusted EBITDA rose 8.2%: Growth was 7.8% on a constant currency basis, against the 8.2% reported figure, with the difference reflecting currency movements.
- Nordion fourth-quarter revenue fell on harvest timing: Nordion fourth-quarter segment income fell 18.9% to $29 million, with unfavorable volume and mix partly offset by favorable pricing.
- Nelson Labs full-year revenue fell 3.9%: Nelson Labs full-year segment income rose 6.0% to $73 million, with revenue lower in reported and constant currency terms.
- Adjusted EBITDA margin up year over year: Full-year margin was 51.0% against 49.9% in 2024, and fourth-quarter margin was 51.8% against 52.7%.
From this 10-K
Sotera Health provides sterilization services, microbiological and analytical lab testing and advisory services so that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers. It serves customers in over 50 countries from 62 facilities, and the filing states that in 2025 its customers included over 40 of the top 50 medical device companies and nine of the top ten global pharmaceutical companies. Most of its services are needed for customers to meet government requirements. It runs three businesses, Sterigenics, Nordion and Nelson Labs.
The four quarters: Q1 FY2025 · Q2 FY2025 · Q3 FY2025 · Q4 FY2025
Income statement (profit and loss)
| $ million | FY2025 | FY2024 | FY2023 | On the year | Last 8 years |
|---|---|---|---|---|---|
| Revenue | 1,164 | 1,100 | 1,049 | +5.7% | |
| Cost of revenue | 518 | 498 | 472 | +4.0% | |
| Gross profit | 646 | 602 | 577 | +7.2% | |
| Gross margin | 55.5% | 54.7% | 55.0% | ||
| Selling, general and administrative | 253 | 243 | 237 | +4.2% | |
| Operating income | n/a | 298 | 277 | ||
| Operating margin | n/a | 27.0% | 26.4% | ||
| Pre-tax income | 148 | 114 | 106 | +29.5% | |
| Income tax | 69.6 | 69.5 | 54.7 | +0.1% | |
| Effective tax rate | 47.2% | 61.0% | 51.5% | ||
| Net income | 77.9 | 44.4 | 51.4 | +75.6% | |
| Net margin | 6.7% | 4.0% | 4.9% | ||
| Diluted EPS | $0.27 | $0.16 | $0.18 | +68.8% |
Read more
Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.Cash flow
| $ million | FY2025 | FY2024 | FY2023 | On the year | Last 8 years |
|---|---|---|---|---|---|
| Operating cash flow | 287 | 224 | -148 | +28.1% | |
| Capital expenditure | 138 | 179 | 215 | -22.9% | |
| Free cash flow | 149 | 45.1 | -363 | +230.8% | |
| Free cash flow margin | 12.8% | 4.1% | -34.6% | ||
| Cash from investing | -135 | -179 | -215 | ||
| Cash from financing | -101 | -50.6 | 266 | ||
| Depreciation and amortisation | 94.9 | 84.3 | 76.6 | +12.6% | |
| Share-based compensation | 30.9 | 36.8 | 32.2 | -16.0% | |
| Diluted shares, weighted | 286m | 285m | 283m | +0.5% |
Balance sheet
| $ million | FY2025 | FY2024 | FY2023 | On the year | Last 8 years |
|---|---|---|---|---|---|
| Shareholders' equity | 606 | 405 | 444 | +49.7% | |
| Debt | 2,141 | 2,223 | 2,228 | -3.7% | |
| Operating lease liabilities | 29.9 | 24.5 | 20.1 | +22.2% | |
| Finance lease liabilities | 93.8 | 95.3 | 63.8 | -1.5% | |
| Other liabilities | 393 | 324 | 374 | +21.2% | |
| Total liabilities and equity | 3,263 | 3,072 | 3,130 | +6.2% | |
| Goodwill | 1,103 | 1,081 | 1,111 | +2.0% | |
| Intangible assets | 288 | 318 | 416 | -9.3% | |
| Cash and equivalents | 345 | 277 | 296 | +24.3% | |
| Receivables | 139 | 140 | 148 | -0.7% | |
| Inventory | 54.4 | 49.2 | 48.3 | +10.6% | |
| Other assets | 1,333 | 1,206 | 1,110 | +10.5% | |
| Total assets | 3,263 | 3,072 | 3,130 | +6.2% |
10-K for the year ended 31 December 2025, filed 24 February 2026: the filing.